 |
|
Atypical Antipsychotics Have Very Different Adverse Effect Profiles and Should Not Be Lumped Together
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
While the work of Rochon et al1 is laudable in intent, it is, unfortunately, misleading in its title and in its conclusions, although clearly stating the authors' caveats about these very conclusions. The authors made the same mistake the Food and Drug Administration made in categorizing the atypical antipsychotic drugs as a single class. In this study, 80% of their patients were initially dispensed risperidone; 18%, olanzapine; and 2%, quetiapine fumarate. While these drugs are all labeled "atypical," there is no consensus definition of what "atypical" means. These drugs have very different movement disorder adverse effects. Data from a study on Parkinson disease (PD) suggest that quetiapine does not worsen motor function, whereas olanzapine and risperidone do.2 Because all the dementing illnesses are associated with parkinsonism, the effects of these drugs in PD is relevant.3 A recent placebo-controlled trial, in fact, confirms this.4 In the nonelderly, risperidone has been associated . . . [Full Text of this Article]
AUTHOR INFORMATION
Joseph H. Friedman, MD
RELATED ARTICLES
Atypical Antipsychotics Have Very Different Adverse Effect Profiles and Should Not Be Lumped Together—Reply
Sudeep Gill, Connie Marras, Geoffrey M. Anderson, Philip E. Lee, Jerry H. Gurwitz, and Paula A. Rochon
Arch Intern Med. 2006;166(5):586-587.
EXTRACT
| FULL TEXT
Atypical Antipsychotics and Parkinsonism
Paula A. Rochon, Therese A. Stukel, Kathy Sykora, Sudeep Gill, Susan Garfinkel, Geoffrey M. Anderson, Sharon-Lise T. Normand, Muhammad Mamdani, Philip E. Lee, Ping Li, Susan E. Bronskill, Connie Marras, and Jerry H. Gurwitz
Arch Intern Med. 2005;165(16):1882-1888.
ABSTRACT
| FULL TEXT
|
